Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 6/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | PIM2 | Q9P1W9 | 4/20 | 0.32 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.31 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
| ▸ | CLK1 | P49759 | 1/20 | 0.30 |
| ▸ | CLK2 | P49760 | 1/20 | 0.30 |
| ▸ | CLK3 | P49761 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.30 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2177240 | 0.72 | PIM2 (0.31) | PIM1HIF1APIM2 | |
| SCHEMBL31256683 | 0.71 | CHRM4 (0.42) | CHRM4PIM1HRH4TRPM8PDE10A | |
| SCHEMBL2176989 | 0.64 | LARS1 (0.32) | — | |
| SCHEMBL2178113 | 0.64 | PIM1 (0.53) | PIM1PIM2PIM3 | |
| SCHEMBL2177397 | 0.61 | — | — | |
| SCHEMBL15273472 | 0.61 | LRRK2 (0.44) | CHRM4HIF1ATRPM8PTGER4LRRK2 | |
| SCHEMBL15273471 | 0.61 | LRRK2 (0.44) | CHRM4HIF1ATRPM8PTGER4LRRK2 | |
| SCHEMBL31256687 | 0.58 | PTGER4 (0.36) | CHRM4HRH4PDE10APTGER4 | |
| SCHEMBL24469154 | 0.58 | TRIM58 (0.42) | HIF1ATRPM8PDE10ATLR7CLK4 | |
| SCHEMBL2177953 | 0.57 | ALDH1A1 (0.43) | CHRM4PIM2PIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682991-B2 | Tricyclic compounds for use as kinase inhibitors | FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) | 2017-06-20 | — | — | US | disclosed |
| EP-2519526-B1 | TRICYCLIC COMPOUNDS FOR USE AS KINASE INHIBITORS | CT NAC INVESTIGACIONES ONCOLOGICAS CNIO (ES) | 2014-03-26 | — | — | EP | disclosed |
| US-20130065881-A1 | Tricyclic Compounds for Use as Kinase Inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (ES) | 2013-03-14 | — | — | US | disclosed |
| EP-2519526-A1 | TRICYCLIC COMPOUNDS FOR USE AS KINASE INHIBITORS | Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) | 2012-11-07 | — | — | EP | disclosed |
| WO-2011080510-A1 | TRICYCLIC COMPOUNDS FOR USE AS KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065881-A1 | Tricyclic Compounds for Use as Kinase Inhibitors | PIM1, PIM2, PIM3 | CHRM4 3993/4885PIM1 1/4885HIF1A 1264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.